WHO ICTRP trial
How SGLT2-I and and Angiotensin receptor blockers together affect Diabetic…
CTRI/2022/05/042657 · Clinical Trials Registry India (CTRI) · Recruiting
Key facts
| Trial ID | CTRI/2022/05/042657 |
|---|---|
| Public title | How SGLT2-I and and Angiotensin receptor blockers together affect Diabetic kidney disease |
| Scientific title | The Descriptive Study on Assessment of the effects of combination of SGLT 2 Inhibitors (SGLT2-I) and Renin Angiotensin Aldosterone System (RAAS) Blockers (RAAS-I) on the renal functions of patients of diabetic kidney disease (DKD) on the population of patients from the Southern part of West Bengal… |
| Primary sponsor | Thakurpukur Medical Society |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Recruiting |
| Study type | Observational |
| Countries | India |
| Conditions | Health Condition 1: E112- Type 2 diabetes mellitus with kidney complications |
| Interventions | Intervention1: Not applicable: Not applicable Control Intervention1: Not applicable: Not applicable |
| Registration date | May 19, 2022 |
| Target size | 600 |
| Secondary IDs | NIL |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: